This site uses cookies to provide you with a more responsive and personalised service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print this page

Life sciences

Shifting demographics. Shrinking margins. Evolving regulations. Rising R&D costs. There is little doubt that life sciences companies face a range of significant challenges for the years ahead. To adapt effectively, pharmaceutical, medical devices and biotechnology organizations must not only accelerate their development processes, they must also re-examine their underlying operational strategies.

Deloitte’s professionals have experience working with life sciences companies across the country to enhance revenues, manage costs and improve asset turnover. Our industry specialists can help you refine your business models through innovative partnerships, improved processes and more effective compliance — ultimately strengthening both patient care and stakeholder value.

 Canada’s biopharmaceutical companies compete  Helping Canada’s biopharmaceutical companies compete
"Take the lead" explores the challenges facing the biopharmaceutical industry and identifies global best practices Canadian organizations can adopt to enhance their competitive positioning.

Featured insights

  • Significant premiums over stock market prices in biotechnology acquisitions
    This article explores the reasons why there have been several acquisitions of biotechnology companies at significant premiums to their stock market prices. Learn more.

Related links

2011 Canadian consumer health survey
View archive
Convergence in the Life Sciences industry
A Deloitte Research report


Featured content

  • ExternalURL
  • ExternalURL
  • ExternalURL
    Future of life sciences in Canada
    Strategies for growth in Canada’s life sciences organizations

Learn more